Replies to post #87141 on Biotech Values

[biomaven0]

Well I just listened to the Kantarjian presentation of the Ariad data. He strongly suggested that the drug might be expected to work in FLT3 positive AML, saying it was likely better than AC220 (from Ambit). If he's right, that's a very big additional market before you even get to solid tumors.

Peter